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expression of transgene. Transgene expression following exposure to the reporter gene 
was assessed by enzyme activity (Galacto-Light assay) and by a histochemical method 
after X-Gal staining. Transgene expression following transfection with eNOS was 
assessed by histochemical staining and enzyme activity was assessed by the conversion 
of L-arginine to L-citrulline. After gene transfer, I'J-galactosidase or eNOS were expressed 
in endothelium and edventitia but not media. Enzyme activity of eNOS or the reporter 
gene transfer was greater in the pulmonary artery of patients with scleroderma than in 
control arteries. Effects of transgene expression on vascular function were examined by 
recording isometric tension 1 day after transduction. After precontraction with phenyleph- 
dne, ecetylcholine produced significantly less relaxation in vessels from scleroderma 
than in vessels from normal arteries. Relaxation in response to ecetylcholine was greater 
in pulmonary arteries from both normal and scleroderma arteries that were transfected 
with AdeNOS than in vessels treated with vehicle or Adbetagal. Vasorelaxation in 
response to ecetylcholine was inhibited by N-omega-nitro-L-arginine. Responses to 
sodium nitroprusside were similar after treatment with vehicle alone, Adbetagal, or Ade- 
NOS in both groups of arteries. Thus, overaxpression of eNOS with an adenoviral vector 
improves impaired NO-mediated relaxation in human pulmonary arteries and that aden- 
oviral gene-transfer expression is greater in the pulmonary artedes from patients with 
scleroderma than from normal human controls. 
1081-78 Thrombin Generation After  the  Abrupt Cessation of 
Intravenous Unfractionated Heparin Is Mediated by the  
Extrinsic Coagulation Pathway 
Richard C. Becker, YouFu Li, Frederick A. Spencer, University of Massechusetts Medical 
School, Worcester, Massachusetts. 
A "rebound" increase in prothrombotic potential has been observed biochemicaEly and 
clinically after the abrupt cessation of unfrectionated heparin (UFH) among patients with 
acute coronary syndromes. The responsible mechanism(s) have not been determined. 
Methods: In a single-center pilot study, 30 patients with either unstable angina or non-ST 
segment elevation MI who had received a continuous IV infusion of UFH for 48h under- 
went serial blood sampling for markers of thrombin generation (F1.2), intrinsic pathway 
activation (factor Xlla) and extrinsic pathway activation (factor Vlla, tissue factor pathway 
inhibitor [TFPI]) immediately before (baseline) and lh, 4h, and 24h after treatment was 
terminated, The Results are summarized below. Conclusions: Thrombin generation 
increases progressively after UFH cessation and correlates with activation of the extrin- 
sic but not the intrinsic coagulation pathway. Future investigation should focus on the 
effects of pharmacologic thrombin antagonist-mediated prothrombotic potential and the 
specific contribution of impaired tissue factor-directed vascular thromboresistance. 
Coagulation Measurements Over Time (mean values) 
Time Point Heparin F1.2 Factor Xlla Factor Vlla TFPI 
(U/ml) (nM) (ng/ml) (mU/ml) (ng/ml) 
Baseline 0.56 2.22 3.08 38.7 t26.6 
lh 0.34 2.36 3.17 32.2 87.7 
4h 0.12 2.84 3.63 62.6"+ 72,2"*+ 
24h 0.00" 4.40* 2.75 48.4 + 85.3"++ 
*Compared to baseline value, p=O.O01; +correlation with Ft.2 (r=0.85)++; inverse cor- 
relation with F1.2 (r=0.82 and 0.78, respectively) 
1081-79 Long-Term Treatment With Phosphodieaterase Type 5 
Inhibitor Improves Pulmonary Hypertension Caused by 
Congestive Heart Failure Through a Natrluretic 
Peptldes-cGMP Pathway 
Takashi Yamamoto. Atsuyuki Wada, Masato Ohnishi, Takayoshi Tsutamoto, Masanod 
Fujii, Takehiro Matsumoto, Tomoyuki Takayama, Masahiko Kinoshita, Shiga University of 
Medical Science, Otsu, Japan, 
BACKGROUND: Congestive heart failure (CHF) accompanies pulmonary hypertension 
(PH) and PH is an independent predictor of mortality in patients with CHF. Natriuretic 
peptides (NPs) system is activated in CHF and regulates pulmonary vascular tone, how- 
ever, the degradation of cGMP in pulmonary vasculatures is accelerated by phosphodi- 
esterase type 5 (PDE5) in CHF, METHOD: To examine (1) whether long-term treatment 
with a specific PDE5 inhibitor amedolates PH, we administered "1"-1032 (1 mg/kg/day, 
n=7) to dogs with CHF induced by rapid pacing (270 beats/min, 22 days), and CHF con- 
trol dogs were given placebo (n=7); and (2) whether NPs-cGMP pathway is involved in 
the therapeutic effects of "1"-1032 on PH, we injected a specific NPs receptor antagonist, 
HS-142-1 (HS, 3 mg/kg) to clogs after long-term treatment with "1"-1032. RESULTS: In this 
experimentally produced CHF, mean pulmonary pressure (MPAP) and the ratio of right 
ventricular weight/body weight (RV/BW) were significantly increased from 16 to 31 
mmHg, from 1.4 to 2.3, P<0,001, respectively. Plasma atrial natriuretic peptide (ANP) 
and cGMP levels were also higher than the normal dogs (460 vs 46 pg/ml, P<0.001 and 
35 vs 15 pmol/ml, P<0.01, respectively), Long-term treatment of T-1032 further increased 
plasma cGMP level compared with the CHF control dogs (72 vs 35 pmol/ml, p<0.05) 
despite no significant difference in plasma ANP levels (424 vs 460 pg/ml). Without 
adverse hypotensive effect on systemic blood pressure (BP, 94 vs 87 mmHg), T1032 sig- 
nificantly decreased MPAP and RV/BW by 26 % and 18 %, respectively (P<0.05) com- 
pared with those of the CHF control dogs. In the T-1032 group, HS significantly 
suppressed plasma cGMP level from 72 to 40 pmol/ml, p<0.05. MPAP but not BP was 
elevated from 23 to 29 mmHg, p<O.05. In the CHF control group, HS also decreased 
plasma cGMP level from 34 to 10 pmol/ml (p<0.05) but did not affect MPAP. CONCLU- 
SION: Long-term treatment with T-1032 exerts an important role in the regulation of PH 
through the NPs-cGMP pathway without hypotensive effect in CHF. PDE5 inhibitor may 
be an attractive therapeutic agent for CHF-induced PH. 
1081-80 Ef fects  of  the  Oral Endothe l in  Receptor Antagonist 
Bosentan on Echocardlographic and Doppler Measures 
in Patients With Pulmonary Arterial Hypertension 
~ ,  Alan L. Hioderiiter, Adam Torbicki, Gerald Simonneau, Nilda Espinola- 
Zabaleta, Guido Rocchi, Marcin Kurzyna, Andrew Kronenperg, Robert Frantz, Nagueh 
Sherif, Robyn Barst, Karl Dujardin, Richard Channick, for the BREATHE-1 Echo 
Substudy Group, Institute of Cardiology, University of Bologna, Bologna, Italy. 
Background: Bosentan, an orally active dual endothelin receptor antagonist, improves 
symptoms, exercise capacity, and hemodynamics in patients with pulmonary artedal 
hypertension. In the present study, the effects of bosentan (125 or 250 mg bid) on 
echocardiographic and Doppler variables were analysed in a subgroup of 85 patients 
with WHO class Iti and IV pulmonary arterial hypertension enrolled in the prospective, 
double blind, placebo-controlled BREATHE-1 study. 
Methods: The majority of patients (84%) had primary pulmonary hypertension. 29 
patients received placebo and 56 received bosentan in a 1:2 randomization procedure. 
6-minute walk tests and echocardiograms were performed at baseline and after 16 
weeks. Echocardiograms were recorded in 13 centers and measurements were per- 
formed in a core laboratory. 
Results: Baseline clinical, hemodynamic and echocardiegraphic characteristics were 
similar in the placebo and bosentan groups. On baseline evaluation, echocardiographic 
and Doppler variables were consistent with marked abnormalities of nght (RV) and left 
(LV) ventricular structure and function. The treatment effect (difference between treat- 
ment groups in the mean change at week 16) on 6-minute walking distance was 37 m in 
favor of bosentan (p = 0.036). Time velocity integrals of the LV outflow tract and of mitral 
inflow were improved in the bosentan group and resulted in a treatment effect on Dop- 
pler-derived cardiac index of + 0.4 I/min/m 2 (p = 0.007). Treatment effects of bosentan on 
other echocardiograPhic and Doppler parameters were as follows: E/A ratio = + 0.18 (p = 
0.004), LV end-diastolic area = + 4.2 cm 2 (p = 0.003), LV systolic eccentricity index = - 
0.12 (p = 0.047), RV end-systolic area = - 2.3 cm 2 (p = 0.057), LV/RV diastolic areas ratio 
= + 0,16 (p= 0.04), RV diastolic remodeling index (minor/major axis ratio) = - 0.06 (p = 
0.004), RV ejection time = + 22 msec (p = 0,007), Doppler RV (Tei) index = - 0.06 (p = 
0.03), inferior vena cava minimum diameter = - 0.22 cm (p = 0.03), pericardial effusion 
score = - 0.54 (p = 0.05). 
Conclusions: Bosentan improves RV systolic function and LV early diastolic filling and 
leads to reverse ventricular remodeling in patients with pulmonary arterial hypertension. 
1081-81 Oral S i ldenaf i l  Is an Ef fect ive and Speci f ic  Pulmonary 
Vasodilator in Patients With Pulmonary Arterial 
Hypertension 
Evangelos D. Michelakis, Wavne Tvmchak, Dale Lien, Linda DaSilva, Kyoko Hashimoto, 
Stephen L. Archer, University of Alberta, Edmonton, Alberta, Canada. 
Background: The prognosis of patients with severe pulmonary hypertension (PHT) is 
poor. To determine prognosis and guide chronic therapy, an acute trial of a selective pul- 
monary vasodilator, usually inhaled nitric oxide (iNO), is performed during cardiac cathe- 
terization. We hypothesized that oral sildenafil, a phosphodiesterase V inhibitor, is a safe 
and effective alternative to iND. 
Methods: We studied 12 consecutive patients (mean±SEM, 43±2 years, 8 female) 
referred during one year, for consideration of heart-lung transplantation or as a guide to 
medical therapy. All but one were functional class IV. Subjects had primary PHT (8), pul- 
monary arterial hypertension (2) or secondary PHT (2). Hemodynamics and serum cyclic 
guanosine monophosphate levels (c-GMP) were measured at baseline and at peak 
effects of iNO (80 ppm), sildenafil (75 mg) or their combination. 
Results: The decrease in pulmonary vascular resistance was similar with iNO (-20±6%) 
and sildenafil (-25±3%) while sildenafil+iNO was more effective than iNO alone (-32±5%, 
p<0.03). Sildenafil and sildenafil+iNO increased cardiac output (15±6 and 15±4%, 
respectively) whereas iNO did not (0,3±3.0%, p<0.003), iNO increased, whereas sildena- 
fil tended to decrease pulmonary-capillary wedge pressure (+17±7 versus -9±8%, p< 
0.001 ). Systemic arterial pressure was similar amongst groups and did not decrease with 
treatment, cGMP levels increased similarly with iNO and sildenafil and their combination 
elevated cGMP more (p<0.05). 
Conclusions: A single oral dose of sildenafil is as effective and selective a pulmonary 
vasodilator as iNO. Sildenafil may be superior to iNO in that it causes greater increase in 
cardiac output and does not increase wedge pressure. Future studies are indicated to 
establish whether sildenafil could also be effective chronically. 
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1082-72 Carbon Monoxide Decreases Pulmonary Vascular 
Resistance and Blocks Hypoxic Pulmonary 
Vasoconstriction in the Rat 
Albert L. Hymen. Syed R. Baber, Robert L Johnson, Philip J. Kadowitz, Tulane 
University Medical Center, New Orleans, Louisiana. 
The effects of carbon monoxide (CO) and the heme oxygenase inhibitor chromium mesopo- 
rphydn (CM) ~n the pulmonary circulation was investigated in the intact-chest rat. Pulmo- 
nary arterial (PA) and wedge pressures were measured using a newly developed right-heart 
